EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis

Coronel, Emmanuel; Cazacu, Irina M.; Sakuraba, Atsushi; Chavez, Adriana; Uberoi, Angad S.; Geng, Yimin; Tomizawa, Yutaka; Săftoiu, Adrian; Shin, Eun Ji; Taniguchi, Cullen M.; Koong, Albert C.; Herman, Joseph M.; Bhutani, Manoop S.

doi:10.1016/j.gie.2018.10.047

Cited by 33 publications

(36 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delivery of radiotherapy to the pancreas can be challenging due to the movements of the pancreas during respiration, and the proximity of vulnerable organs at risk of radiation toxicity such as the stomach, duodenum and other parts of the small bowel (11,12). Thus, fiducial markers as an aid for better localization and tracking have gained wide appeal in pancreatic radiation therapy, particularly when onboard imaging systems do not have sufficient resolution to identify interfaces between the bowel and the tumor (13). However, placing a fiducial carries some risk.…”

Section: Introductionmentioning

confidence: 99%

Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer

Moningi

Jaoude

Kouzy

et al. 2021

Advances in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer

Moningi

Jaoude

Kouzy

et al. 2021

Advances in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…[95] Fiducial placement using EUS has a high success rate and helps to plan stereotactic radiotherapy. [9697]…”

Section: Ablative Techniquesmentioning

confidence: 99%

Therapeutic EUS: New tools, new devices, new applications

2019

View full text Add to dashboard Cite

Linear echoendoscopes with large instrument channels enable EUS-guided interventions in organs and anatomical spaces in proximity to the gastrointestinal tract. Novel devices and tools designed for EUS-guided transluminal interventions allow various new applications and improve the efficacy and safety of these procedures. New-generation biopsy needles provide higher histology rates and require less passes. Specially designed stents and stent insertion devices enable intra- and extra-hepatic bile and pancreatic duct stenting as well as gallbladder drainage. Currently, EUS-guided biliary drainage in obstructive jaundice due to malignant distal bile duct obstruction is feasible and safe when ERCP has failed. It might replace ERCP as first choice intervention in future. EUS-guided transmural stenting is regarded as the preferred intervention in the management of symptomatic peripancreatic fluid collections. Creating a new anastomosis between different organs such as gastrojejunostomy has also become possible with lumen-apposing stents. EUS-guided creation of a gastrogastrostomy is a promising novel technique to access the excluded stomach to facilitate conventional ERCP in patients with Roux-en-Y gastric bypass anatomy. The role of EUS in tumor ablation and targeted angiotherapy is also constantly expanding. In this review, we report on the newest developments of therapeutic EUS within the past 4 years.

show abstract

“…EUS-guided fiducial placement for GI malignancies is feasible, with a high technical success rate of 98%, according to a recent meta-analysis that included more than 1000 patients 8 . The same study showed that EUS-guided fiducial placement is safe, with a pooled adverse events rate of 4%.…”

Section: Fiducial Markers Overviewmentioning

confidence: 99%

“…The same study showed that EUS-guided fiducial placement is safe, with a pooled adverse events rate of 4%. Reported adverse events included mild acute pancreatitis, minor bleeding, fever, vomiting, abdominal pain, rectal pain, or elevated liver enzymes 8 …”

Section: Fiducial Markers Overviewmentioning

confidence: 99%